291 related articles for article (PubMed ID: 31272081)
1. Gastric neuroendocrine neoplasias: manifestations and comparative outcomes.
Felder S; Jann H; Arsenic R; Denecke T; Prasad V; Knappe-Drzikova B; Maasberg S; Wiedenmann B; Pavel M; Pascher A; Pape UF
Endocr Relat Cancer; 2019 Sep; 26(9):751-763. PubMed ID: 31272081
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
3. [Establishment of risk model for predicting the progression within 1 year of patients with gastric neuroendocrine neoplasms and its value of prediction].
Peng X; Zhang Y; Bao Y; Zhou L; Muo Z; Chen H; Zhi F; Liu S; Chen J; Chen Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1247-1251. PubMed ID: 27928794
[TBL] [Abstract][Full Text] [Related]
4. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
[TBL] [Abstract][Full Text] [Related]
5. Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?
Grillo F; Albertelli M; Annunziata F; Boschetti M; Caff A; Pigozzi S; Ferone D; Mastracci L
Endocrine; 2016 Jul; 53(1):58-62. PubMed ID: 26362059
[TBL] [Abstract][Full Text] [Related]
6. Comparison of WHO 2000 and WHO 2010 classifications of gastroenteropancreatic neuroendocrine tumors.
Karakuş E; Helvacı A; Ekinci O; Dursun A
Turk J Gastroenterol; 2014 Feb; 25(1):81-7. PubMed ID: 24918137
[TBL] [Abstract][Full Text] [Related]
7. Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center.
Lewkowicz E; Trofimiuk-Müldner M; Wysocka K; Pach D; Kiełtyka A; Stefańska A; Sowa-Staszczak A; Tomaszewska R; Hubalewska-Dydejczyk A
Pol Arch Med Wewn; 2015; 125(5):337-46. PubMed ID: 25924181
[TBL] [Abstract][Full Text] [Related]
8. Recent classifications systems for gastroenteropancreatic neuroendocrine tumors A single-center experience.
Yagmur Y; Söğutcü N; Gümüş S
Ann Ital Chir; 2020; 91():598-604. PubMed ID: 32989209
[TBL] [Abstract][Full Text] [Related]
9. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.
Pape UF; Jann H; Müller-Nordhorn J; Bockelbrink A; Berndt U; Willich SN; Koch M; Röcken C; Rindi G; Wiedenmann B
Cancer; 2008 Jul; 113(2):256-65. PubMed ID: 18506737
[TBL] [Abstract][Full Text] [Related]
10. Pathology - grading and staging of GEP-NETs.
Capelli P; Fassan M; Scarpa A
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):705-17. PubMed ID: 23582914
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
[TBL] [Abstract][Full Text] [Related]
12. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
[TBL] [Abstract][Full Text] [Related]
13. High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Improved Prognostic Stratification With the New World Health Organization 2019 Classification: A Validation Study From a Single-Institution Retrospective Analysis.
Hayes AR; Furnace M; Shah R; Rundell C; Muller G; Dehbi HM; Luong TV; Toumpanakis C; Caplin ME; Krell D; Thirlwell C; Mandair D
Pancreas; 2021 Apr; 50(4):516-523. PubMed ID: 33939663
[TBL] [Abstract][Full Text] [Related]
14. Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort.
Lithgow K; Venkataraman H; Hughes S; Shah H; Kemp-Blake J; Vickrage S; Smith S; Humphries S; Elshafie M; Taniere P; Diaz-Cano S; Dasari BVM; Almond M; Ford S; Ayuk J; Shetty S; Shah T; Geh I
Sci Rep; 2021 Sep; 11(1):17947. PubMed ID: 34504148
[TBL] [Abstract][Full Text] [Related]
15. Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study.
Panzuto F; Campana D; Massironi S; Faggiano A; Rinzivillo M; Lamberti G; Sciola V; Lahner E; Manuzzi L; Colao A; Annibale B
Dig Liver Dis; 2019 Oct; 51(10):1456-1460. PubMed ID: 31175013
[TBL] [Abstract][Full Text] [Related]
16. Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria.
Ozkara S; Aker F; Yesil A; Senates E; Canbey C; Yitik A; Gonen C
Hepatogastroenterology; 2013 Oct; 60(127):1665-72. PubMed ID: 24627925
[TBL] [Abstract][Full Text] [Related]
17. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis.
Laffi A; Spada F; Bagnardi V; Frassoni S; Pisa E; Rubino M; Barberis M; Fazio N
J Endocrinol Invest; 2022 Feb; 45(2):317-325. PubMed ID: 34282554
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
19. Subgroup analysis of patients with G2 gastroenteropancreatic neuroendocrine tumors.
Hauck L; Bitzer M; Malek N; Plentz RR
Scand J Gastroenterol; 2016 Jan; 51(1):55-9. PubMed ID: 26137871
[TBL] [Abstract][Full Text] [Related]
20. An 11-year retrospective study: clinicopathological and survival analysis of gastro-entero-pancreatic neuroendocrine neoplasm.
Liu H; Xie R; Zhao Z; Xu D; Yang K; Ding M; Tan D; Liao W; Han X; Zhang J; Shen D; Yuan J; Xu Z; Fei J
Medicine (Baltimore); 2020 Aug; 99(33):e21682. PubMed ID: 32872039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
